Explore the vast range of titles available.

\"A child wonders where peanut butter comes from and learns about the jobs of peanut farmers and how peanuts are harvested, and how peanuts are made into peanut butter and packaged at a factory. This illustrated narrative nonfiction book includes a map of where peanuts are grown, glossary, and further resources\"--Provided by publisher.

Children 4 to 11 months of age who were at high risk for development of peanut allergy were assigned to consumption or avoidance of peanuts until 60 months of age. Peanut allergy was more than five times as likely to develop in children assigned to peanut avoidance. The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, reaching rates of 1.4 to 3.0%, 1 – 3 and peanut allergy is becoming apparent in Africa and Asia. 4 , 5 This allergy is the leading cause of anaphylaxis and death due to food allergy and imposes substantial psychosocial and economic burdens on patients and their families. 6 Peanut allergy develops early in life and is rarely outgrown. 7 – 9 Clinical practice guidelines from the United Kingdom in 1998 9 and from the United States in 2000 10 recommended the exclusion of allergenic foods from the diets of infants at . . .

Opposites go together like Peanut Butter and Jelly!

A previous trial showed that early consumption of peanuts resulted in fewer cases of allergy than did avoidance. In a follow-up study, all participants avoided peanuts from 5 to 6 years of age; those who had eaten peanuts in early life retained the ability to do so. Peanut allergy is a common and potentially life-threatening food allergy for which prevention and treatment strategies are required. 1 – 5 The Learning Early about Peanut Allergy (LEAP) trial showed that among infants at high risk for allergy, the sustained consumption of peanut, beginning in the first 11 months of life, resulted in an 81% lower rate of peanut allergy at 60 months of age than the rate among children who avoided peanuts. 6 , 7 In a study of oral immunotherapy to hen’s egg white, although children achieved unresponsiveness to an oral food challenge with egg, the majority had a reversion to egg . . .

Dietary avoidance is recommended for peanut allergies. We evaluated the sustained effects of peanut allergy oral immunotherapy (OIT) in a randomised long-term study in adults and children. In this randomised, double-blind, placebo-controlled, phase 2 study, we enrolled participants at the Sean N Parker Center for Allergy and Asthma Research at Stanford University (Stanford, CA, USA) with peanut allergy aged 7–55 years with a positive result from a double-blind, placebo-controlled, food challenge (DBPCFC; ≤500 mg of peanut protein), a positive skin-prick test (SPT) result (≥5 mm wheal diameter above the negative control), and peanut-specific immunoglobulin (Ig)E concentration of more than 4 kU/L. Participants were randomly assigned (2·4:1·4:1) in a two-by-two block design via a computerised system to be built up and maintained on 4000 mg peanut protein through to week 104 then discontinued on peanut (peanut-0 group), to be built up and maintained on 4000 mg peanut protein through to week 104 then to ingest 300 mg peanut protein daily (peanut-300 group) for 52 weeks, or to receive oat flour (placebo group). DBPCFCs to 4000 mg peanut protein were done at baseline and weeks 104, 117, 130, 143, and 156. The pharmacist assigned treatment on the basis of a randomised computer list. Peanut or placebo (oat) flour was administered orally and participants and the study team were masked throughout by use of oat flour that was similar in look and feel to the peanut flour and nose clips, as tolerated, to mask taste. The statistician was also masked. The primary endpoint was the proportion of participants who passed DBPCFCs to a cumulative dose of 4000 mg at both 104 and 117 weeks. The primary efficacy analysis was done in the intention-to-treat population. Safety was assessed in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT02103270. Between April 15, 2014, and March 2, 2016, of 152 individuals assessed, we enrolled 120 participants, who were randomly assigned to the peanut-0 (n=60), peanut-300 (n=35), and placebo groups (n=25). 21 (35%) of peanut-0 group participants and one (4%) placebo group participant passed the 4000 mg challenge at both 104 and 117 weeks (odds ratio [OR] 12·7, 95% CI 1·8–554·8; p=0·0024). Over the entire study, the most common adverse events were mild gastrointestinal symptoms, which were seen in 90 of 120 patients (50/60 in the peanut-0 group, 29/35 in the peanut-300 group, and 11/25 in the placebo group) and skin disorders, which were seen in 50/120 patients (26/60 in the peanut-0 group, 15/35 in the peanut-300 group, and 9/25 in the placebo group). Adverse events decreased over time in all groups. Two participants in the peanut groups had serious adverse events during the 3-year study. In the peanut-0 group, in which eight (13%) of 60 participants passed DBPCFCs at week 156, higher baseline peanut-specific IgG4 to IgE ratio and lower Ara h 2 IgE and basophil activation responses were associated with sustained unresponsiveness. No treatment-related deaths occurred. Our study suggests that peanut OIT could desensitise individuals with peanut allergy to 4000 mg peanut protein but discontinuation, or even reduction to 300 mg daily, could increase the likelihood of regaining clinical reactivity to peanut. Since baseline blood tests correlated with week 117 treatment outcomes, this study might aid in optimal patient selection for this therapy. National Institute of Allergy and Infectious Diseases.

On-farm losses of peanuts (Arachis hypogaea L, Fabales: Fabaceae) pose a persistent threat to the sustainable production and value of peanuts in the United States. This study presents empirical data on the spatial distribution of subterranean insect pests and various quality aspects of peanuts. Surveys were conducted in 20 randomly selected peanut fields in 10 counties in Northeast, Southeast, and Southwest Georgia. The primary insect pests found in Georgia's peanut production counties were Pangaeus bilineatus (Say), Elasmopalpus lignosellus (Zeller), and Diabrotica undecimpunctata Howardi. In the northeast counties, a high prevalence of P. bilineatus led to a significant increase in insect-damaged pods (%IDP), insect-damaged kernels (%IDK), discolored kernels (%DK), pod weight loss (%PWL), and kernel weight loss (%KWL). Similarly, southeast counties had a high %DK, cracked pods (%CP), and E. lignosellus infestation. In southwest counties, predominantly high D. undecimpunctata infestations resulted in the highest %IDR Moisture content (%MC) was excessively high in all the counties (22.19%-23.17%). Preharvest aflatoxin contamination in peanuts was prevalent across all studied locations, particularly in counties with a high incidence of P. bilineatus and may cause increased risk in aflatoxin levels along the supply chain. Nevertheless, the diverse regional abundance of insect pests and the widespread presence of aflatoxins in Georgia's peanut fields offer valuable insights for developing integrated pest management strategies targeting subterranean insect pests. This is especially crucial in addressing the impact of P. bilineatus, E. lignosellus, and D. undecimpunctata on aflatoxins content of peanuts and determining the pathway for mitigation of aflatoxin contaminations in peanuts at harvest. Key words: peanut, insect pest, insect-damaged kernel, cracked pod, aflatoxin residue